Glucose control in diabetes: Which target level to aim for?

Journal of Internal Medicine

Volumn 272, Issue 1, 2012, Pages 1-12

  Laakso, M ^a   Cederberg, H ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Cardiovascular disease; Diabetes mellitus; Diabetic complications; HbA 1c; Type 2 diabetes mellitus

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C;

BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SMOKING;

BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DYSLIPIDEMIAS; EVIDENCE-BASED MEDICINE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIC AGENTS; INCIDENCE; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SMOKING;

EID: 84862653555     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2012.02528.x     Document Type: Review

References (75)

1. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-7.
2. Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997; 14: S1-85.
3. International Diabetes Federation. Available at: (accessed 31 December 2011).
4. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-25.
5. Andersson CX, Gustafson B, Hammarstedt A, Hedjazifar S, Smith U. Inflamed adipose tissue, insulin resistance and vascular injury. Diabetes Metab Res Rev 2008; 24: 595-603.
6. Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 2001; 249: 225-35.
7. Bainey KR, Jugdutt BI. Increased burden of coronary artery disease in South-Asians living in North America. Need for an aggressive management algorithm. Atherosclerosis 2009; 204: 1-10.
8. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008; 371: 1800-9.
9. Reusch JE, Wang CC. Cardiovascular disease in diabetes: where does glucose fit in? J Clin Endocrinol Metab 2011; 96: 2367-76.
10. Laakso M. Cardiovascular disease in type 2 diabetes from population to man to mechanisms: the Kelly West Award Lecture 2008. Diabetes Care 2010; 33: 442-9.
11. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-91.
12. Klein R, Klein BE, Moss SE. Relation of glycaemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med 1996; 124: 90-6.
13. Juutilainen A, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Similarity of the impact of type 1 and type 2 diabetes on cardiovascular mortality in middle-aged subjects. Diabetes Care 2008; 31: 714-9.
14. Laakso M. Heart in diabetes: a microvascular disease. Diabetes Care 2011; 34(Suppl 2): S145-9.
15. Cerami A. The unexpected pathway to the creation of the HbA1c test and the discovery of AGE's. J Intern Med 2011; doi:.
16. Sacks DB, Bruns DE, Goldstein DE, Maclaren NK, McDonald JM, Parrott M. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2002; 48: 436-72.
17. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-86.
18. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-12.
19. 1c assay in the diagnosis of diabetes. Diabetes Care 2009; 32: 1327-34.
20. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2012; 35(Suppl 1): S64-71.
21. 1c) for the diagnosis of diabetes mellitus. 2011.
22. 1c. J Intern Med 2011; doi:.
23. 1c for diagnosing diabetes mellitus. Am J Med 2011; 124: 395-401.
24. Kumar PR, Bhansali A, Ravikiran M et al. Utility of glycated hemoglobin in diagnosing type 2 diabetes mellitus: a community-based study. J Clin Endocrinol Metab 2010; 95: 2832-5.
25. 1c test. J Intern Med 2011; doi:.
26. Nathan DM, Kuenen J, Borg R et al. Translating the HbA1c assay into estimated average glucose values. Diabetes Care 2008; 31: 1473-8.
27. 1c level and future risk of diabetes: a systematic review. Diabetes Care 2010; 33: 1665-73.
28. American Diabetes Association. Standards of medical care in diabetes - 2012. Diabetes Care 2012; 35(Suppl 1): S11-63.
29. Diabetes Control and Complications Trial (DCCT) Research Group. The absence of glycaemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 1996; 45: 1289-98.
30. Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN; for the DCCT/EDIC Research Group. Effect of glycaemic exposure on the risk of microvascular complications in the Diabetes Control and Compliactions Trial - revisited. Diabetes 2008; 57: 995-1001.
31. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95, 783 individuals followed for 12.4years. Diabetes Care 1999; 22: 233-40.
32. Selvin E, Marinopoulos S, Berkenblit G et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004; 141: 421-31.
33. 1c levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts. Diabetologia 2011; 54: 1327-34.
34. The Emerging Risk Factor Collaboration. Diabetes mellitus, fasting glucose concentration, and risk of cascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010; 375: 2215-22.
35. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000; 342: 381-9.
36. Martin CL, Albers J, Herman WH et al. Neuropathy among the diabetes control and complications trial cohort 8years after trial completion. Diabetes Care 2006; 29: 340-4.
37. DCCT/EDIC Research Group, de Boer IH, Sun W et al. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365: 2366-76.
38. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-17.
39. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
40. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-89.
41. Ismail-Beigi F, Craven T, Banerji MA et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376: 419-30.
42. Chew EY, Ambrosius WT, Davis MD et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-44.
43. Patel A, MacMahon S, Chalmers J et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-72.
44. Zoungas S, Chalmers J, Ninomiya T et al. Association of HbA(1c) levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia 2012; 55: 636-43.
45. Duckworth W, Abraira C, Moritz T et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009; 360: 129-39.
46. Moritz T, Duckworth W, Abraira C. Veterans Affairs diabetes trial - corrections. N Engl J Med 2009; 361: 1024-5.
47. The University Group Diabetes Program. A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. V. Evaluation of pheniformin therapy. Diabetes 1975; 24(Suppl 1): 65-184.
48. Knatterud GL, Klimt CR, Levin ME, Jacobson ME, Goldner MG. Effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes. VII. Mortality and selected nonfatal events with insulin treatment. JAMA 1978; 240: 37-42.
49. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
50. Home PD, Pocock SJ, Beck-Nielsen H et al. Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis. N Engl J Med 2007; 357: 28-38.
51. Nathan DM, Cleary PA, Backlund JY et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-53.
52. Nathan DM, Zinman B, Cleary PA et al. Modern-day clinical course of type 1 diabetes mellitus after 30years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169: 1307-16.
53. Stettler C, Allemann S, Jüni P et al. Glycaemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials. Am Heart J 2006; 152: 27-38.
54. Gerstein HC, Miller ME, Byington RP et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-59.
55. Gerstein HC, Miller ME, Genuth S et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011; 364: 818-28.
56. Bonds DE, Miller ME, Bergenstal RM et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: b4909.
57. 1c and all-cause mortality during a median 3.4-year follow-up of glycaemic treatment in the ACCORD trial. Diabetes Care 2010; 33: 983-90.
58. Reaven PD, Moritz TE, Schwenke DC et al. Intensive glucose lowering therapy reduces cardiovascular disease events in VADT participants with lower calcified coronary atherosclerosis. Diabetes 2009; 58: 2642-8.
59. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343: d4169.
60. Turnbull FM, Abraira C, Anderson RJ et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 2009; 52: 2288-98.
61. Ray KK, Seshasai SR, Wijesuriya S et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765-72.
62. Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 2009; 151: 394-403.
63. Mannucci E, Monami M, Lamanna C, Gori F, Marchionni N. Prevention of cardiovascular disease through glycaemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2009; 19: 604-12.
64. Zhang CY, Sun AJ, Zhang SN et al. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis. Ann Med 2010; 42: 305-15.
65. Castagno D, Baird-Gunning J, Jhund PS et al. Intensive glycaemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37, 229 patient meta-analysis. Am Heart J 2011; 162: 938-48.
66. Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycaemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 2009; 32: 187-92.
67. Standl E, Schnell O, Ceriello A. Postprandial hyperglycaemia and glycaemic variability: should we care? Diabetes Care 2011; 34(Suppl 2): S120-7.
68. 1c -Derived Average Glucose (ADAG) study. Diabetologia 2011; 54: 69-72.
69. Skyler JS, Bergenstal R, Bonow RO et al. Intensive glycaemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 2009; 53: 298-304.
70. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30.
71. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycaemic control. Endocr Pract 2009; 15: 40-59.
72. International Diabetes Federation. Clinical Guidelines Taskforce. Global Guideline for Type 2 Diabetes. 2005. Available at: (accessed 30 December 2011).
73. Brown A, Reynolds R, Bruemmer D. Intensive glycaemic control and cardiovascular disease: an update. Nat Rev Cardiol 2010; 7: 369-75.
74. Abraira C, Colwell J, Nuttall F et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial. Veterans affairs cooperative study on glycemic control and complicationsin type II diabetes. Arch Intern Med 1997; 157: 181-8.
75. Dargie HJ, Hildebrandt PR, Riegger GA et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association Functional Class I or II Heart Failure. J Am Coll Cardiol 2007; 49: 1696-704.